Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). CRS is a debilitating inflammatory disease that affects millions of people, causing symptoms like nasal congestion, facial pain, and pressure, yet many lack effective, long-lasting treatment options. Lyra Therapeutics' technology is designed to deliver medicine directly to the affected sinonasal tissues, providing sustained relief for up to six months with a single administration.

The company's lead product candidate, LYR-210, is a bioabsorbable nasal mesh designed to deliver continuous anti-inflammatory medication for the treatment of CRS. LYR-210 is currently in Phase 3 clinical trials for CRS patients with surgically naïve anatomy. Lyra Therapeutics' second product candidate, LYR-220, is being developed for CRS patients with post-surgical anatomy and is in Phase 2 clinical trials.

Lyra Therapeutics offers a number of flexible work arrangements to employees. These include self-managed vacation and holidays, flexible work arrangements, and an employee assistance program. Additionally, Lyra Therapeutics provides catered lunches on Wednesdays to promote team bonding and employee satisfaction.

Lyra Therapeutics offers a comprehensive benefits package designed to support employee well-being and financial security. They provide comprehensive health insurance, including medical, dental, and vision, as well as flexible spending accounts and a health reimbursement account. Employees enjoy a healthy work-life balance with self-managed vacation and holidays, flexible work arrangements, and catered lunches on Wednesdays. Financial security is provided through competitive compensation, equity awards, life and disability insurance, and a 401K plan.

Lyra Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). Their mission is to provide a new treatment option for the millions of individuals who suffer from CRS, a debilitating inflammatory disease that causes months or years of nasal congestion, facial pain and pressure, and nasal discharge. Lyra Therapeutics' technology is designed to deliver long-acting medication directly to sinonasal tissues for sustained periods with a single administration, offering a potential solution to the unmet need for effective, long-lasting treatment options.

Lyra Therapeutics fosters a dynamic, diverse, and intellectually-challenging work environment. They value a culture of collaboration, innovation, and dedication to improving the lives of patients with chronic rhinosinusitis. The company offers competitive compensation, stock-based equity awards, and a comprehensive benefits package, including health insurance, flexible work arrangements, and generous parental leave.

Lyra Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace. They believe that a diverse team of talented individuals allows them to best serve their patients. Their commitment to DEI is demonstrated by their dedication to providing competitive compensation, benefits, and growth opportunities to all employees. They offer flexible work arrangements, catered lunches, and a culture that values and respects diverse perspectives, making Lyra a welcoming and supportive environment for all.